Pentax Medical Acquires Majority Stake in PlasmaBiotics SAS

Pentax Medical, a division of the HOYA Group, announced that it has acquired a controlling interest in PlasmaBiotics SAS, based in Paris, France, a company that designs, manufactures and markets devices for drying and storage of endoscopes. Hygiene is a key strategic pillar for Pentax Medical. The investment in PlasmaBiotics will strengthen PENTAX Medical’s hygiene portfolio and its continued focus on reducing cross-contamination risks to enhance patient safety in endoscopy.  Other portfolio additions of note include the recently launched DEC Video Duodenoscope, with a sterile disposable elevator cap and single-use reprocessing accessories. PlasmaBiotics specializes in the drying and storage of endoscopes. Its core products are the PlasmaTYPHOON, an ultra-fast drying unit for endoscopes, and the PlasmaBAG, a single-use device for active storage with plasma. The products deliver superior and efficient performance by significantly reducing endoscope reprocessing cycle times. These innovations minimize the risk of bacterial contamination through a highly effective drying mechanism for the endoscopic channels and active storing of the endoscopes with plasma.  The PlasmaBiotics products also integrate fairly easily into most current endoscope reprocessing protocols.

“The investment in PlasmaBiotics enables us to provide our customers with an efficient and effective drying and storage solution to address unmet hygiene needs associated with endoscope reprocessing. For duodenoscopes we have worked to address the hygiene of the Albarran lever and the hoods through our disposable elevator cap and now with PlasmaBiotics we can provide highly innovative technology for the critical step of drying and storing of endoscopes,” said Rainer Burkard, Managing Director of PENTAX Europe GmbH and President of Pentax Medical EMEA. “PlasmaBiotics is excited to join the HOYA Group as a part of the Pentax Team. This is an important step for PlasmaBiotics as we continue to receive enthusiastic responses from our clients on PlasmaTYPHOON’s performance, ease of use and effectiveness.  Having the additional global resources of PENTAX Medical will enable us to accelerate and expand our commercialization activities,” commented Dr Daniel Vinteler, CEO and Founder of PlasmaBiotics.

“Our PlasmaBiotics investment continues the HOYA Group’s externalization activities to identify and source innovative and differentiated technology and products from early-stage and emerging companies. Through our HOYA Group’s M&A and Venture Capital teams, and our Divisional Business Development groups, we aim to foster and build strong collaborations and alliances with industry and academia,” said Augustine Yee, Chief Legal Officer and Global Head of Corporate Development and Affairs of HOYA Corporation.  Financial terms of the transaction were not disclosed. – Medical Buyer Bureau